NT-proBNP与肺动脉高压长期结局的关联:GRIPHON试验分析
GRIPHON试验事后分析评估NT-proBNP阈值在肺动脉高压中的预后价值及对selexipag治疗反应的影响。采用基线三分位阈值和2015 ESC/ERS指南切点对患者分组,发现基线和随访NT-proBNP分类均高度预测未来发病率/死亡率事件(P<0.0001)。Selexipag在三个NT-proBNP类别中均降低事件风险,中、低NT-proBNP亚组获益更明显。
要点
- 基线及随访NT-proBNP分类均高度预测PAH患者未来发病率/死亡率事件(P<0.0001)。
- Selexipag在低、中、高NT-proBNP类别中均降低发病率/死亡率事件风险。
- 中、低NT-proBNP亚组中selexipag治疗获益更明显(交互P值0.20和0.007)。
核心结论
- NT-proBNP水平在PAH中具有预后相关性,并首次提供NT-proBNP水平与治疗反应关联的证据。
- 采用两套相似阈值支持低、中、高NT-proBNP分类作为ESC/ERS指南多参数风险评估方法的一部分。
研究设计与样本
- 事件驱动的GRIPHON试验事后分析,患者随机接受selexipag或安慰剂。
- NT-proBNP定期测量,按基线三分位阈值(<271 ng/L;271至1165 ng/L;>1165 ng/L)和2015 ESC/ERS指南切点(<300 ng/L;300至1400 ng/L;>1400 ng/L)分为低、中、高亚组。
主要发现
- 两种阈值下,基线和随访NT-proBNP分类均高度预测研究期间未来发病率/死亡率事件(P<0.0001)。
- 时间依赖分析中,与高NT-proBNP水平患者相比,selexipag治疗的低和中NT-proBNP水平患者发生发病率/死亡率事件的风险分别降低92%和83%,安慰剂治疗的低和中NT-proBNP水平患者分别降低90%和56%。
- Selexipag在基线和时间依赖分析中均降低所有3个NT-proBNP类别的发病率/死亡率事件风险,中、低NT-proBNP亚组治疗获益更明显(交互P值基线分析0.20,时间依赖分析0.007)。
关键数值与推荐
- 基线三分位阈值:低<271 ng/L;中271至1165 ng/L;高>1165 ng/L。
- 2015 ESC/ERS指南切点:低<300 ng/L;中300至1400 ng/L;高>1400 ng/L。
临床怎么用
- NT-proBNP低、中、高分类可用于PAH多参数风险评估,支持ESC/ERS指南推荐。
- Selexipag在各NT-proBNP类别中均降低发病率/死亡率事件风险,中、低NT-proBNP亚组获益更明显。
局限性
- 事后分析,NT-proBNP分类非随机分组。
- 交互P值在基线分析中为0.20,未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: NT-proBNP (N-terminal pro brain natriuretic peptide) levels are included in the multiparametric risk assessment approach for pulmonary arterial hypertension (PAH) outlined in PAH guidelines. However, data supporting the use of NT-proBNP risk thresholds in assessing prognosis in PAH are limited. The GRIPHON trial (Prostacyclin [PGI2] Receptor Agonist In Pulmonary Arterial Hypertension) provides an opportunity to assess the prognostic value of NT-proBNP thresholds in a controlled clinical trial and to evaluate the response to selexipag according to these thresholds. METHODS: The event-driven GRIPHON trial randomly assigned patients to selexipag or placebo. NT-proBNP was measured at regular intervals in GRIPHON. Here, patients were categorized post hoc into low, medium, and high NT-proBNP subgroups according to 2 independent sets of thresholds: (1) baseline tertiles: <271 ng/L; 271 to 1165 ng/L; >1165 ng/L; and (2) 2015 European Society of Cardiology/European Respiratory Society guidelines cutoffs: <300 ng/L; 300 to 1400 ng/L; >1400 ng/L. Hazard ratios (selexipag versus placebo) with 95% CIs were calculated for the primary end point (composite morbidity/mortality events) by NT-proBNP category at baseline using Cox proportional-hazards models, and at any time during the exposure period using a time-dependent Cox model. RESULTS: With both thresholds, baseline and follow-up NT-proBNP categories were highly prognostic for future morbidity/mortality events during the study ( P<0.0001). In the time-dependent analysis, the risk of experiencing a morbidity/mortality event was 92% and 83% lower in selexipag-treated patients with a low and medium NT-proBNP level, and 90% and 56% lower in placebo-treated patients with a low and medium NT-proBNP level, in comparison with patients with a high NT-proBNP level. Selexipag reduced the risk of morbidity/mortality events across all 3 NT-proBNP categories in both the baseline and time-dependent analyses, with a more pronounced treatment benefit of selexipag seen in the medium and low NT-proBNP subgroups (interaction P values 0.20 and 0.007 in the baseline and time-dependent analyses). CONCLUSIONS: These analyses further establish the prognostic relevance of NT-proBNP levels in PAH and provide first evidence for the association of NT-proBNP level and treatment response. Using 2 similar sets of thresholds, these analyses support the relevance of the low, medium, and high NT-proBNP categories as part of the multiparametric risk assessment approach outlined in the European Society of Cardiology/European Respiratory Society guidelines for the management of PAH patients. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01106014.
引用
- Chin KM, Rubin LJ, Channick R, et al. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. Circulation. 2019. PMID: 30982349. doi:10.1161/CIRCULATIONAHA.118.039360
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。